nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Hypotensive—Furosemide—dilated cardiomyopathy	0.0401	0.0526	CcSEcCtD
Tapentadol—Lethargy—Spironolactone—dilated cardiomyopathy	0.0199	0.0261	CcSEcCtD
Tapentadol—Ataxia—Spironolactone—dilated cardiomyopathy	0.0183	0.0241	CcSEcCtD
Tapentadol—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.0169	0.0222	CcSEcCtD
Tapentadol—Drug interaction—Furosemide—dilated cardiomyopathy	0.0158	0.0207	CcSEcCtD
Tapentadol—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.0155	0.0204	CcSEcCtD
Tapentadol—Memory impairment—Lisinopril—dilated cardiomyopathy	0.014	0.0184	CcSEcCtD
Tapentadol—CYP2C9—cardial valve—dilated cardiomyopathy	0.0127	0.627	CbGeAlD
Tapentadol—Mental disability—Furosemide—dilated cardiomyopathy	0.0127	0.0167	CcSEcCtD
Tapentadol—Drug interaction—Lisinopril—dilated cardiomyopathy	0.0118	0.0155	CcSEcCtD
Tapentadol—Lethargy—Furosemide—dilated cardiomyopathy	0.0108	0.0142	CcSEcCtD
Tapentadol—Irritability—Furosemide—dilated cardiomyopathy	0.0101	0.0133	CcSEcCtD
Tapentadol—Confusional state—Spironolactone—dilated cardiomyopathy	0.00967	0.0127	CcSEcCtD
Tapentadol—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00959	0.0126	CcSEcCtD
Tapentadol—Somnolence—Spironolactone—dilated cardiomyopathy	0.00852	0.0112	CcSEcCtD
Tapentadol—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00847	0.0111	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00828	0.0109	CcSEcCtD
Tapentadol—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00796	0.0105	CcSEcCtD
Tapentadol—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0079	0.0104	CcSEcCtD
Tapentadol—Urticaria—Spironolactone—dilated cardiomyopathy	0.00761	0.01	CcSEcCtD
Tapentadol—Irritability—Lisinopril—dilated cardiomyopathy	0.0076	0.00998	CcSEcCtD
Tapentadol—Ataxia—Lisinopril—dilated cardiomyopathy	0.00749	0.00983	CcSEcCtD
Tapentadol—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00725	0.00952	CcSEcCtD
Tapentadol—Urethral disorder—Furosemide—dilated cardiomyopathy	0.0072	0.00945	CcSEcCtD
Tapentadol—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00719	0.00945	CcSEcCtD
Tapentadol—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00712	0.00935	CcSEcCtD
Tapentadol—Visual impairment—Furosemide—dilated cardiomyopathy	0.00707	0.00929	CcSEcCtD
Tapentadol—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00706	0.00928	CcSEcCtD
Tapentadol—Eye disorder—Furosemide—dilated cardiomyopathy	0.00686	0.00901	CcSEcCtD
Tapentadol—SLC6A2—sympathetic nervous system—dilated cardiomyopathy	0.00685	0.338	CbGeAlD
Tapentadol—Pruritus—Spironolactone—dilated cardiomyopathy	0.00678	0.00891	CcSEcCtD
Tapentadol—Angiopathy—Furosemide—dilated cardiomyopathy	0.00666	0.00875	CcSEcCtD
Tapentadol—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00663	0.00871	CcSEcCtD
Tapentadol—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00656	0.00861	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00639	0.0084	CcSEcCtD
Tapentadol—Malnutrition—Furosemide—dilated cardiomyopathy	0.00639	0.00839	CcSEcCtD
Tapentadol—Dizziness—Spironolactone—dilated cardiomyopathy	0.00634	0.00833	CcSEcCtD
Tapentadol—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00634	0.00832	CcSEcCtD
Tapentadol—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00623	0.00818	CcSEcCtD
Tapentadol—Depression—Lisinopril—dilated cardiomyopathy	0.00612	0.00803	CcSEcCtD
Tapentadol—Vomiting—Spironolactone—dilated cardiomyopathy	0.00609	0.008	CcSEcCtD
Tapentadol—Rash—Spironolactone—dilated cardiomyopathy	0.00604	0.00794	CcSEcCtD
Tapentadol—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00604	0.00793	CcSEcCtD
Tapentadol—Vision blurred—Furosemide—dilated cardiomyopathy	0.00602	0.00791	CcSEcCtD
Tapentadol—Headache—Spironolactone—dilated cardiomyopathy	0.006	0.00789	CcSEcCtD
Tapentadol—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00596	0.00783	CcSEcCtD
Tapentadol—Agitation—Furosemide—dilated cardiomyopathy	0.00587	0.00771	CcSEcCtD
Tapentadol—Vertigo—Furosemide—dilated cardiomyopathy	0.00574	0.00754	CcSEcCtD
Tapentadol—Nausea—Spironolactone—dilated cardiomyopathy	0.00569	0.00748	CcSEcCtD
Tapentadol—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00561	0.00736	CcSEcCtD
Tapentadol—Hallucination—Lisinopril—dilated cardiomyopathy	0.00548	0.0072	CcSEcCtD
Tapentadol—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00544	0.00714	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.0054	0.0071	CcSEcCtD
Tapentadol—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.0054	0.00709	CcSEcCtD
Tapentadol—Dry mouth—Furosemide—dilated cardiomyopathy	0.00532	0.00699	CcSEcCtD
Tapentadol—Confusional state—Furosemide—dilated cardiomyopathy	0.00526	0.00691	CcSEcCtD
Tapentadol—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00521	0.00685	CcSEcCtD
Tapentadol—Shock—Furosemide—dilated cardiomyopathy	0.00513	0.00674	CcSEcCtD
Tapentadol—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00511	0.00672	CcSEcCtD
Tapentadol—Skin disorder—Furosemide—dilated cardiomyopathy	0.00507	0.00665	CcSEcCtD
Tapentadol—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00504	0.00662	CcSEcCtD
Tapentadol—Angiopathy—Lisinopril—dilated cardiomyopathy	0.005	0.00656	CcSEcCtD
Tapentadol—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00496	0.00652	CcSEcCtD
Tapentadol—Chills—Lisinopril—dilated cardiomyopathy	0.00494	0.00649	CcSEcCtD
Tapentadol—Hypotension—Furosemide—dilated cardiomyopathy	0.00487	0.0064	CcSEcCtD
Tapentadol—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00483	0.00634	CcSEcCtD
Tapentadol—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00479	0.0063	CcSEcCtD
Tapentadol—Tension—Lisinopril—dilated cardiomyopathy	0.0047	0.00618	CcSEcCtD
Tapentadol—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00468	0.00615	CcSEcCtD
Tapentadol—Nervousness—Lisinopril—dilated cardiomyopathy	0.00466	0.00612	CcSEcCtD
Tapentadol—Somnolence—Furosemide—dilated cardiomyopathy	0.00464	0.00609	CcSEcCtD
Tapentadol—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00453	0.00595	CcSEcCtD
Tapentadol—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00452	0.00593	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.0045	0.00591	CcSEcCtD
Tapentadol—Fatigue—Furosemide—dilated cardiomyopathy	0.0045	0.00591	CcSEcCtD
Tapentadol—Tremor—Lisinopril—dilated cardiomyopathy	0.00449	0.0059	CcSEcCtD
Tapentadol—Constipation—Furosemide—dilated cardiomyopathy	0.00446	0.00586	CcSEcCtD
Tapentadol—Angioedema—Lisinopril—dilated cardiomyopathy	0.00438	0.00575	CcSEcCtD
Tapentadol—Vertigo—Lisinopril—dilated cardiomyopathy	0.00431	0.00566	CcSEcCtD
Tapentadol—Syncope—Lisinopril—dilated cardiomyopathy	0.0043	0.00565	CcSEcCtD
Tapentadol—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0043	0.00564	CcSEcCtD
Tapentadol—Palpitations—Lisinopril—dilated cardiomyopathy	0.00424	0.00556	CcSEcCtD
Tapentadol—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00421	0.00553	CcSEcCtD
Tapentadol—Cough—Lisinopril—dilated cardiomyopathy	0.00418	0.00549	CcSEcCtD
Tapentadol—Urticaria—Furosemide—dilated cardiomyopathy	0.00414	0.00544	CcSEcCtD
Tapentadol—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00408	0.00536	CcSEcCtD
Tapentadol—Anxiety—Lisinopril—dilated cardiomyopathy	0.00407	0.00534	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00405	0.00532	CcSEcCtD
Tapentadol—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00399	0.00524	CcSEcCtD
Tapentadol—Confusional state—Lisinopril—dilated cardiomyopathy	0.00395	0.00518	CcSEcCtD
Tapentadol—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00391	0.00514	CcSEcCtD
Tapentadol—Oedema—Lisinopril—dilated cardiomyopathy	0.00391	0.00514	CcSEcCtD
Tapentadol—Infection—Lisinopril—dilated cardiomyopathy	0.00389	0.00511	CcSEcCtD
Tapentadol—Shock—Lisinopril—dilated cardiomyopathy	0.00385	0.00506	CcSEcCtD
Tapentadol—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00384	0.00505	CcSEcCtD
Tapentadol—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00382	0.00502	CcSEcCtD
Tapentadol—Skin disorder—Lisinopril—dilated cardiomyopathy	0.0038	0.00499	CcSEcCtD
Tapentadol—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00378	0.00497	CcSEcCtD
Tapentadol—Asthenia—Furosemide—dilated cardiomyopathy	0.00374	0.00491	CcSEcCtD
Tapentadol—Pruritus—Furosemide—dilated cardiomyopathy	0.00369	0.00485	CcSEcCtD
Tapentadol—Hypotension—Lisinopril—dilated cardiomyopathy	0.00366	0.0048	CcSEcCtD
Tapentadol—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00357	0.00469	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00356	0.00468	CcSEcCtD
Tapentadol—Insomnia—Lisinopril—dilated cardiomyopathy	0.00354	0.00465	CcSEcCtD
Tapentadol—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00351	0.00461	CcSEcCtD
Tapentadol—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00349	0.00458	CcSEcCtD
Tapentadol—Somnolence—Lisinopril—dilated cardiomyopathy	0.00348	0.00457	CcSEcCtD
Tapentadol—Dizziness—Furosemide—dilated cardiomyopathy	0.00345	0.00453	CcSEcCtD
Tapentadol—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00344	0.00452	CcSEcCtD
Tapentadol—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.0034	0.00447	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00338	0.00444	CcSEcCtD
Tapentadol—Fatigue—Lisinopril—dilated cardiomyopathy	0.00337	0.00443	CcSEcCtD
Tapentadol—Constipation—Lisinopril—dilated cardiomyopathy	0.00335	0.00439	CcSEcCtD
Tapentadol—Vomiting—Furosemide—dilated cardiomyopathy	0.00332	0.00436	CcSEcCtD
Tapentadol—Rash—Furosemide—dilated cardiomyopathy	0.00329	0.00432	CcSEcCtD
Tapentadol—Dermatitis—Furosemide—dilated cardiomyopathy	0.00329	0.00431	CcSEcCtD
Tapentadol—Headache—Furosemide—dilated cardiomyopathy	0.00327	0.00429	CcSEcCtD
Tapentadol—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00322	0.00424	CcSEcCtD
Tapentadol—Urticaria—Lisinopril—dilated cardiomyopathy	0.00311	0.00408	CcSEcCtD
Tapentadol—Nausea—Furosemide—dilated cardiomyopathy	0.0031	0.00407	CcSEcCtD
Tapentadol—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00288	0.00379	CcSEcCtD
Tapentadol—Asthenia—Lisinopril—dilated cardiomyopathy	0.00281	0.00369	CcSEcCtD
Tapentadol—Pruritus—Lisinopril—dilated cardiomyopathy	0.00277	0.00364	CcSEcCtD
Tapentadol—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00268	0.00352	CcSEcCtD
Tapentadol—Dizziness—Lisinopril—dilated cardiomyopathy	0.00259	0.0034	CcSEcCtD
Tapentadol—Vomiting—Lisinopril—dilated cardiomyopathy	0.00249	0.00327	CcSEcCtD
Tapentadol—Rash—Lisinopril—dilated cardiomyopathy	0.00247	0.00324	CcSEcCtD
Tapentadol—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00246	0.00324	CcSEcCtD
Tapentadol—Headache—Lisinopril—dilated cardiomyopathy	0.00245	0.00322	CcSEcCtD
Tapentadol—Nausea—Lisinopril—dilated cardiomyopathy	0.00232	0.00305	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00159	0.00729	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00159	0.00727	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00154	0.00707	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00154	0.00707	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00144	0.00657	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00143	0.00656	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00143	0.00656	CbGpPWpGaD
Tapentadol—SLC6A4—Monoamine Transport—TNF—dilated cardiomyopathy	0.00134	0.00615	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00133	0.0061	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00126	0.00576	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00126	0.00576	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00121	0.00554	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00121	0.00554	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00121	0.00553	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00117	0.00535	CbGpPWpGaD
Tapentadol—SLC6A2—Monoamine Transport—TNF—dilated cardiomyopathy	0.00115	0.00528	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00115	0.00524	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00113	0.0052	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00112	0.00515	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00112	0.00514	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—FAS—dilated cardiomyopathy	0.00112	0.00511	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.0011	0.00505	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00106	0.00486	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00106	0.00486	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00106	0.00486	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00106	0.00486	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00104	0.00478	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.00101	0.00463	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00101	0.00463	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000993	0.00455	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000989	0.00453	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000988	0.00452	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000986	0.00451	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000984	0.00451	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000967	0.00443	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000962	0.0044	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000962	0.0044	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000917	0.0042	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000915	0.00419	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.00091	0.00417	CbGpPWpGaD
Tapentadol—HTR3A—Ion channel transport—RAF1—dilated cardiomyopathy	0.0009	0.00412	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000896	0.0041	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000896	0.0041	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000894	0.00409	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000891	0.00408	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000886	0.00406	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00087	0.00398	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000866	0.00396	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000863	0.00395	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000852	0.0039	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000843	0.00386	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000843	0.00386	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000836	0.00383	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000833	0.00382	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000832	0.00381	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000829	0.00379	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000829	0.00379	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000829	0.00379	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000819	0.00375	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000817	0.00374	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000784	0.00359	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000776	0.00355	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000773	0.00354	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00077	0.00353	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000759	0.00348	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000757	0.00347	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000749	0.00343	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000739	0.00339	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000732	0.00335	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000732	0.00335	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000727	0.00333	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000725	0.00332	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000718	0.00329	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000713	0.00326	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000713	0.00326	CbGpPWpGaD
Tapentadol—CYP2C9—heart—dilated cardiomyopathy	0.000702	0.0347	CbGeAlD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000701	0.00321	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000682	0.00312	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000681	0.00312	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00068	0.00311	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000662	0.00303	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000661	0.00303	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000659	0.00302	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000654	0.003	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000648	0.00297	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000642	0.00294	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000642	0.00294	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000642	0.00294	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00064	0.00293	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TAZ—dilated cardiomyopathy	0.000622	0.00285	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000615	0.00282	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000614	0.00281	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000607	0.00278	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000606	0.00277	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000597	0.00273	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000578	0.00265	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000575	0.00263	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000574	0.00263	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000567	0.0026	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000563	0.00258	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SDHA—dilated cardiomyopathy	0.000562	0.00258	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000548	0.00251	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000543	0.00248	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000543	0.00248	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000538	0.00246	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000534	0.00245	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000533	0.00244	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00052	0.00238	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00052	0.00238	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000517	0.00237	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TAZ—dilated cardiomyopathy	0.000505	0.00231	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000504	0.00231	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000494	0.00226	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000489	0.00224	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000486	0.00223	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000485	0.00222	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000468	0.00214	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SDHA—dilated cardiomyopathy	0.000457	0.00209	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000456	0.00209	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000417	0.00191	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000414	0.00189	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000414	0.00189	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000396	0.00181	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000396	0.00181	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000386	0.00177	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000385	0.00176	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000378	0.00173	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000376	0.00172	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000376	0.00172	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000373	0.00171	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000363	0.00166	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000363	0.00166	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000349	0.0016	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000347	0.00159	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000338	0.00155	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000337	0.00154	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000329	0.00151	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000329	0.00151	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000327	0.0015	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000318	0.00146	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000313	0.00143	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000307	0.0014	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000307	0.0014	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000306	0.0014	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000302	0.00138	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000297	0.00136	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000294	0.00134	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000289	0.00132	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000285	0.00131	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000279	0.00128	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000279	0.00128	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000278	0.00128	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000278	0.00128	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000276	0.00126	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000274	0.00126	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000271	0.00124	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000265	0.00121	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000259	0.00119	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000253	0.00116	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000253	0.00116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000251	0.00115	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00025	0.00114	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000244	0.00112	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00024	0.0011	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000238	0.00109	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000236	0.00108	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000234	0.00107	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000232	0.00106	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.00023	0.00105	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000224	0.00103	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000224	0.00102	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000222	0.00102	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000222	0.00102	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000219	0.001	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000218	0.001	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000217	0.000992	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000215	0.000984	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000214	0.000981	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000213	0.000974	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000206	0.000945	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000205	0.000941	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000203	0.000931	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000203	0.00093	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.0002	0.000915	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000198	0.000905	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000196	0.000899	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000196	0.000897	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000195	0.000891	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000195	0.000891	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000187	0.000854	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000185	0.000848	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000181	0.000829	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000178	0.000816	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000175	0.000802	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000174	0.000795	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000171	0.000782	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000168	0.000769	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000166	0.00076	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000165	0.000753	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000165	0.000753	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000162	0.000741	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000158	0.000722	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000153	0.0007	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GPX1—dilated cardiomyopathy	0.000153	0.0007	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000151	0.00069	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00015	0.000685	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CD36—dilated cardiomyopathy	0.000149	0.000681	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000148	0.000678	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000142	0.00065	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000141	0.000646	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000139	0.000637	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AGT—dilated cardiomyopathy	0.000134	0.000613	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000131	0.0006	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000128	0.000584	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000126	0.000579	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000126	0.000576	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	0.000124	0.000568	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000124	0.000567	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000122	0.000559	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	0.000121	0.000554	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AGT—dilated cardiomyopathy	0.00012	0.00055	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00012	0.00055	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000119	0.000547	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000116	0.000533	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000115	0.000526	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.00011	0.000505	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	0.000109	0.000498	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGT—dilated cardiomyopathy	0.000105	0.000482	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000105	0.00048	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000105	0.000479	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000103	0.000472	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.68e-05	0.000443	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	9.32e-05	0.000427	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	8.9e-05	0.000408	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.49e-05	0.000389	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	8.34e-05	0.000382	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	7.31e-05	0.000335	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.17e-05	0.000328	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	6.18e-05	0.000283	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	5.84e-05	0.000267	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	5.72e-05	0.000262	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	5.68e-05	0.00026	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	5.37e-05	0.000246	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	5.32e-05	0.000244	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	5.23e-05	0.000239	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	5.18e-05	0.000237	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	5.12e-05	0.000234	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	5.01e-05	0.00023	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.71e-05	0.000215	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.67e-05	0.000214	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	4.24e-05	0.000194	CbGpPWpGaD
